Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

B7-33 cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established B7-33 cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • B7-33 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established B7-33 cycle length?
No. We found no human studies that report a treatment duration for B7-33.
What is the longest human study of B7-33?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
B7-33 dosing reference Full research page

References

  1. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1 Chemical Science. 2016
  2. Single chain peptide agonists of relaxin receptors Molecular and Cellular Endocrinology. 2019
  3. B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice Journal of the American Heart Association. 2020
  4. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy Biomedicine & Pharmacotherapy. 2023
  5. B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) European Journal of Pharmacology. 2017
  6. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026) FDA. 2026
  7. ClinicalTrials.gov search for B7-33 as intervention (0 studies returned) ClinicalTrials.gov. 2026
  8. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026